LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers

Bayer

Status: Completed

Conditions: Erectile Dysfunction

Treatments: Drug: Vardenafil (Levitra, BAY38-9456)

Study type: Observational

Funder types: Industry

Identifiers

NCT01207947

LV0702JP (Other Identifier)

13931

Details and patient eligibility

About

Main object is to investigate the safety profile of Levitra in combination use with alpha-blockers in patients with erectile dysfunction used in clinical practice after launch.

In the initial combination date and the first and second observation after initial combination date, number of tablets prescribed, dose of tablets and number of tablets taken until follow-up visit will be investigated. The efficacy and tolerability will be evaluated at 2 months after initial combination date.

Enrollment: 491 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients >/= 18 years
• Enrollment within 7 days after initiation of combination use of Levitra and alpha-blockers

Exclusion Criteria:

Trial design

491 participants in 1 patient group

Group 1

Treatment:

Drug: Vardenafil (Levitra, BAY38-9456)